Suppr超能文献

寻找前进之路:德国、奥地利和瑞士的新冠疫苗接种进展

Finding the way forward: COVID-19 vaccination progress in Germany, Austria and Switzerland.

作者信息

Desson Zachary, Kauer Lukas, Otten Thomas, Peters Jan Willem, Paolucci Francesco

机构信息

Erasmus University Rotterdam, the Netherlands.

CSS Institute for Empirical Health Economics, University of Lucerne, University of Zürich, Switzerland.

出版信息

Health Policy Technol. 2022 Jun;11(2):100584. doi: 10.1016/j.hlpt.2021.100584. Epub 2021 Nov 28.

Abstract

OBJECTIVES

: This paper presents an overview of the procurement and deployment of COVID-19 vaccinations in Germany, Austria and Switzerland (DACH) from the success of the first vaccine trials until the end of August 2021. Data regarding vaccination procurement and deployment is presented, followed by an analysis of the challenges these countries face in improving their vaccination rates.

METHODS

: A review and analysis of available data from the DACH countries was conducted. Data was collected from official government sources whenever possible and supplemented by information from international databases and local reports. The data was analyzed to identify common patterns as well as divergences across the DACH region, especially as they relate to vaccine hesitancy and health policy.

RESULTS

: Following initial global supply problems, the DACH countries were largely successful at administering vaccinations to their populations. However, by the end of August 2021 their vaccination progress had plateaued. This was primarily due to vaccine hesitancy in the region, which is correlated with a multitude of complex factors. These factors need to be better understood before this issue can be effectively addressed. Unlike other countries, the DACH countries have not (yet) used financial incentives or mandates to increase vaccination rates.

CONCLUSIONS

: The DACH countries displayed effective governance in their deployment of COVID-19 vaccines, but vaccine hesitancy is slowing progress. Due to various social and political factors, Germany, Austria and Switzerland have not been able to employ effective policy levers to overcome this barrier and a more nuanced strategy will have to be developed.

PUBLIC INTEREST SUMMARY

: Germany, Austria and Switzerland (DACH) were largely successful at procuring COVID-19 vaccine doses and administering them to their populations. After the first doses were acquired, their vaccination rates continued to steadily rise, but progress began to slow down substantially by August 2021 due in part to vaccine hesitancy. Unlike in other countries, the DACH governments have not been able to implement vaccine mandates to try and overcome this issue due to their specific political and social circumstances. A deeper understanding of the factors driving vaccine hesitancy in the region will be required before effective solutions can be found.

摘要

目标

本文概述了德国、奥地利和瑞士(DACH)从首个新冠疫苗试验成功到2021年8月底期间新冠疫苗的采购和接种情况。文中呈现了疫苗采购和接种的数据,随后分析了这些国家在提高疫苗接种率方面面临的挑战。

方法

对来自DACH国家的现有数据进行了回顾和分析。数据尽可能从官方政府来源收集,并辅以国际数据库和当地报告的信息。对数据进行分析,以确定DACH地区的共同模式以及差异,特别是与疫苗犹豫和卫生政策相关的方面。

结果

在最初的全球供应问题之后,DACH国家在为民众接种疫苗方面基本取得成功。然而,到2021年8月底,它们的疫苗接种进展趋于平稳。这主要是由于该地区的疫苗犹豫现象,这与众多复杂因素相关。在有效解决这个问题之前,需要更好地理解这些因素。与其他国家不同,DACH国家尚未(尚未)使用财政激励措施或强制手段来提高疫苗接种率。

结论

DACH国家在新冠疫苗接种部署方面展现出了有效的治理,但疫苗犹豫正在减缓进展。由于各种社会和政治因素,德国、奥地利和瑞士未能采用有效的政策手段来克服这一障碍,因此必须制定更细致入微的策略。

公众利益总结

德国、奥地利和瑞士(DACH)在采购新冠疫苗剂量并为民众接种方面基本取得成功。在获得首批疫苗后,它们的疫苗接种率持续稳步上升,但到2021年8月,进展开始大幅放缓,部分原因是疫苗犹豫。与其他国家不同,由于其特定的政治和社会情况,DACH国家政府未能实施疫苗强制令来试图克服这一问题。在找到有效解决方案之前,需要更深入地了解该地区推动疫苗犹豫的因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b48a/8627596/1952952af80c/gr1_lrg.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验